Story

UK Grants First European Approval for Eli Lilly's Oral Weight-Loss Pill Orforglipron

ENTHMSVIIDZHZH-TWJAKOHI
Aug 10, 20261 min read
UK Grants First European Approval for Eli Lilly's Oral Weight-Loss Pill Orforglipron
Text size
Background

The United Kingdom has become the first country in Europe to approve Eli Lilly's (NYSE: LLY) oral drug orforglipron for weight management and the treatment of type 2 diabetes. The Medicines and Healthcare products Regulatory Agency (MHRA) announced its authorization on Monday, clearing the path for the new treatment in the UK market.

Regulatory Green Light

The MHRA's decision permits the use of orforglipron, which will be marketed under the brand name Foundayo, for two key indications. According to the agency, the approval covers its use as a treatment for adults with type 2 diabetes and for weight management, including weight loss and weight maintenance.

This authorization is a significant milestone, establishing a new treatment option within the rapidly growing class of drugs known as GLP-1 receptor agonists. Unlike many popular existing treatments in this class that require injections, orforglipron is a once-daily tablet.

Sample IUX Markets – In-articleAd

Market Implications

The approval positions Eli Lilly to compete more directly in the oral segment of the multi-billion dollar market for obesity and diabetes drugs, which is currently dominated by Novo Nordisk's injectable products Ozempic and Wegovy, and its oral tablet Rybelsus. The convenience of a daily pill could be a key differentiator for patients and physicians.

For investors, this development strengthens Eli Lilly's portfolio in a highly lucrative therapeutic area. The company already markets the successful injectable GLP-1/GIP agonist Zepbound (tirzepatide) for weight loss. The addition of an effective oral option like orforglipron could significantly expand its market share and patient reach, pending pricing and availability details.

Read next

More on Stocks
Back to latest news

LATEST